Uncategorized
Arialys Therapeutics Raises $58M to Target Autoimmune Neuropsychiatric Diseases
Arialys is developing an antibody therapeutic, ART5803, to treat anti-NMDA receptor encephalitis (ANRE), one of the most common forms of autoimmune encephalitis….

By Uduak Thomas
Arialys Therapeutics is seeking to make its mark on the neurological market by developing treatments for autoimmune neuropsychiatric diseases. Recently, the company secured $58 million in seed financing to continue developing its first drug, a compound that blocks pathogenic autoantibodies in the central nervous system. Investors in the financing included the company’s founding investors, Avalon BioVentures, Catalys Pacific, and MPM BioImpact, along with Johnson & Johnson Innovation—JJDC, Inc. and Alexandria Venture Investments.
The company officially launched in December 2021 and has been working quietly in stealth mode until now. Arialys is developing an antibody therapeutic, ART5803, to treat anti-NMDA receptor encephalitis (ANRE), one of the most common forms of autoimmune encephalitis. ANRE is caused by crosslinking autoantibodies that drive internalization of NMDA receptors (NMDAR) resulting in seizures and psychosis in patients. ART5803 is a single-arm antibody that treats ANRE by binding to the same epitope as the NMDAR autoantibodies and blocking them from binding. Arialys purchased ART5803 from Astellas Pharma who had been developing the drug as a treatment for ANRE. That deal closed in 2022.
“Recent scientific discoveries have implicated abnormal autoimmune activity in a number of neuropsychiatric diseases, pointing us in a new direction to develop precision medicines for CNS disorders,” Jay Lichter, PhD, president and CEO of Arialys and managing partner of Avalon BioVentures, said in a statement. These discoveries upended a long-held belief among scientists that the immune system does not operate in the central nervous system, he explained in a conversation with GEN. The fact that it does opens up the possibility of developing novel drugs to treat autoimmune diseases that affect the CNS like ANRE.
Although it is one of the most common forms of autoimmune encephalitis, ANRE cases are relatively rare affecting roughly 2,000–3,000 people in the United States annually. Scientists are not sure what triggers the condition but the evidence suggests that it affects women more than men—women are four times more likely to develop ANRE. And it is more common in people under the age of 40.
One risk factor for women is the presence of ovarian teratomas—this occurs in about a third of women with ANRE. The teratomas express NMDA receptors which are treated as foreign entities by the immune system since they are typically only expressed in the brain. Their presence triggers the body to make autoantibodies which go on to attack the NMDA receptors causing the disease.
But the disease can also be caused by infections. For example, Lichter explained that the epitope that the autoantibodies bind to in the body is similar to one present in the Toxoplasmosis gondii parasite. Toxoplasmosis infections are also one of the risk factors for schizophrenia. Fetuses also seem to be at risk of developing the disease if the mother is infected with ANRE during pregnancy—about a seven-fold increased risk for the fetus. Initial symptoms of the disease mimic those of common viral infections and then progress to movement disorders or seizures as well as behavioral symptoms including visual or auditory hallucinations, depression, mania, and more.
The current course of treatment for ANRE is about 18 months of immunosuppressive therapies including steroids and plasmapheresis, which are used as first-line treatments, and drugs like rituximab and cyclophosphamide which are second-line treatments. About half of patients treated this way recover with some lingering neurological symptoms but are otherwise normal. For patients who don’t respond to treatment, the focus shifts to finding strategies that help them manage their symptoms.
Prior to selling the asset to Arialys, Astellas Pharma had already done some preclinical studies testing the efficacy of ART5803 in marmosets with very promising results that made it an attractive candidate for Arialys to pursue.
In their ART5803 studies, Astellas infected marmosets with a cloned human pathogenic antibody from patients with autoimmune encephalitis. Scientists then treated the sick marmosets with the drug, which is a single-arm antibody that binds the same epitope as the pathogenic antibody. Two weeks later, all the infected marmosets treated with the drug had recovered to baseline. Typically, “most CNS drugs take months [but] this worked in a couple of weeks,” Lichter said. Seeing positive results in the marmosets within two weeks was a “profound and significant response. I was blown away.”
Arialys has since replicated Astellas’ results internally with a different marmoset colony, using different protocols, and a different drug delivery mechanism among other changes. And their results were even more robust. Lichter said that Arialys scientists recorded responses in the test subjects as early as one week post-treatment. “We can now leave stealth mode because we are on the fast track to get into the clinic next year.” The company plans to publish data from its studies in the near future.
In fact, the company plans to begin selecting healthy volunteers for testing in Q4 of 2024, and move on to testing the drug in encephalitis patients in the first half of 2025. And Arialys has secured orphan drug designation from the FDA for ART5803 for treating ANRE. “Our initial focus is autoimmune encephalitis and that will be the first half of 2025,” Lichter said. “The second half of 2025, we want to do an autoimmune psychosis trial where we are screening schizophrenia patients.” The reason for that second trial is that about 5% of schizophrenia patients have autoantibodies against NMDA receptors that could play a role in their psychosis symptoms. Arialys hopes that ART5803 could help those patients as well.
Separately, Arialys has an internal discovery program to identify other types of pathogenic autoantibodies and drugs that target them. The company is also developing a backup ANRE treatment that has better brain penetration—that drug has not yet been named. Those studies are occurring in parallel so that by the time the ART5803 clinical trials wrap in 2026, they will have a list of clinical candidates that target a broad range of autoimmune neuropsychiatric conditions. Besides schizophrenia, some research suggests that about 5% each of patients with conditions like dementia, bipolar disease, and severe depression also have autoantibodies against the NMDA receptor. All of those patients could benefit from Arialys’ proposed portfolio adding up to a sizable market for the company.
The post Arialys Therapeutics Raises $58M to Target Autoimmune Neuropsychiatric Diseases appeared first on GEN - Genetic Engineering and Biotechnology News.
depression treatment testing fda clinical trials preclinical geneticUncategorized
Crypto traders shift focus to these 4 altcoins as Bitcoin price flatlines
Bitcoin’s tight range trading points to a potential range expansion and that could trigger a trending move in LINK, MKR, ARB, and THETA.
…

Bitcoin’s tight range trading points to a potential range expansion and that could trigger a trending move in LINK, MKR, ARB, and THETA.
Bitcoin (BTC) has been trading in a tight range for the past three days even as the S&P 500 fell for the last four days of the week. This is a positive sign as it shows that cryptocurrency traders are not panicking and rushing to the exit.
Bitcoin’s supply seems to be gradually shifting to stronger hands. Analyst CryptoCon said citing Glassnode data that Bitcoin’s short-term holders (STHs), investors who have held their coins for 155 days or less, hold the least amount of Bitcoin supply in more than a decade.

In the short term, the uncertainty regarding Bitcoin’s next directional move may have kept traders at bay. That could be one of the reasons for the subdued price action in several large altcoins. But it is not all negative across the board. Several altcoins are showing signs of a recovery in the near term.
Could Bitcoin shake out its slumber and start a bullish move in the near term? Can that act as a catalyst for an altcoin rally? Let’s study the charts of the top-five cryptocurrencies that may lead the charge higher.
Bitcoin price analysis
The bulls have managed to sustain the price above the 20-day exponential moving average ($26,523) but they have failed to start a strong rebound. This indicates a lack of demand at higher levels.

The flattish 20-day EMA and the relative strength index (RSI) near the midpoint show a status of equilibrium between the buyers and sellers. A break below the 20-day EMA will tilt the advantage in favor of the bears. The BTC/USDT pair could then descend to the formidable support at $24,800.
Alternatively, if the price rises from the current level and climbs above the 50-day simple moving average ($26,948), it will signal that buyers are back in the driver's seat. The pair may then attempt a rally to the overhead resistance at $28,143.

BTC has been trading below the moving averages on the 4-hour chart but the bears have failed to start a downward move. This suggests that selling dries up at lower levels. The bulls will try to propel Bitcoin price above the moving averages. If they manage to do that, the pair could rally to $27,400 and subsequently to $28,143.
If bears want to seize control, they will have to sink and sustain BTC price below $26,200. That could first yank it down to $25,750 and then to the $24,800-support.
Chainlink price analysis
Chainlink (LINK) surged above the downtrend line on Sep. 22, indicating a potential trend change in the near term.

The moving averages have completed a bullish crossover and the RSI is in positive territory, indicating that the buyers have the upper hand. On any correction, the bulls are likely to buy the dips to the 20-day EMA ($6.55). A strong rebound off this level will suggest a change in sentiment from selling on rallies to buying on dips.
The bulls will then try to extend the up-move to $8 and eventually to $8.50. If bears want to prevent the up-move, they will have to sink and sustain the LINK/USDT pair below the 20-day EMA.

Both moving averages are sloping up on the 4-hour chart and the RSI is in the positive zone. The bulls have been buying the dips to the 20-EMA indicating a positive sentiment. If LINK price rebounds off the 20-EMA, $7.60 will then be the upside target to watch.
Contrary to this assumption, if Chainlink's price continues lower and skids below the 20-EMA, it will signal profit-booking by the bulls. LINK may then retest the breakout level from the downtrend line. The bears will have to sink it below $6.60 to be back in control.
Maker price analysis
Maker (MKR) turned down from the overhead resistance at $1,370 on Sep. 21, indicating that the bears are trying to defend the level.

The 20-day EMA ($1,226) is the support to watch for on the downside. If the price rebounds off this level, it will suggest that lower levels continue to attract buyers. The bulls will then make one more attempt to drive MK price above the overhead resistance. If they can pull it off, the MKR/USDT pair could accelerate toward $1,759.
Conversely, if the bears sink the price below the 20-day EMA, it will suggest that the bullish momentum has weakened. That could keep the pair range-bound between $980 and $1,370 for a few days.

The moving averages on the 4-hour chart have flattened out and the RSI is just below the midpoint, indicating a balance between supply and demand. If buyers shove the price above $1,306, MKR pric could sprint toward $1,370.
Instead, if the price turns down and breaks below $1,264, it will suggest that the selling pressure is increasing. That could clear the path for a further decline to $1,225. A slide below this support may tilt the short-term advantage in favor of the bears.
Arbitrum price analysis
Arbitrum (ARB) is in a downtrend. The bears are selling on rallies to the 20-day EMA ($0.85) but a positive sign is that the bulls have not ceded much ground. This suggests that the bulls are trying to hold on to their positions as they anticipate a move higher.

The RSI has risen above 40, indicating that the momentum is gradually turning positive. If buyers kick the price above the 20-day EMA, it will suggest the start of a sustained recovery. The ARB/USDT pair could first rally to the 50-day SMA ($0.95) and thereafter to $1.04.
The support on the downside is $0.80 and then $0.78. Sellers will have to drag ARB price below this zone to make room for a retest of the support near $0.74. A break below this level will indicate the resumption of the downtrend.

The 4-hour chart shows that the bears are selling the rallies to the downtrend line. The bears pulled the price below the moving averages but could not sink ARB pric below the immediate support at $0.81. This suggests that the bulls are trying to form a higher low.
Buyers will again try to propel the price above the downtrend line. If they succeed, Arbitrum price is likely to start a strong recovery toward the psychological level of $1. Contrarily, a break below $0.81 can tug ARB price to $0.78 and subsequently to $0.74.
Theta Network price analysis
Theta Network (THETA) soared above the 20-day EMA ($0.61) on Sep. 23, indicating that the bulls have absorbed the supply and are attempting a comeback.

The bears have pulled the price back below the 50-day SMA ($0.64) but the bulls are expected to defend the 20-day EMA. If THETA price turns up from the current level and climbs above the 50-day SMA, it will enhance the prospects of a retest of $0.70.
This is an important level to keep an eye on because if it is scaled, the THETA/USDT pair may reach $0.76. This positive view will invalidate in the near term if the price turns down and plunges below the 20-day EMA. That opens the door for a potential retest of $0.57.

The 4-hour chart shows that the bears are protecting the overhead resistance at $0.65. If buyers want to sustain the bullish momentum, they will have to drive THETA price above $0.65. If they do that, the pair is likely to start a new up-move toward $0.70.
The 20-day EMA is the important support to watch for on the downside. If bears sink the price below this support, it will indicate that the bulls are closing their positions. The pair may then descend toward the support at $0.58.
This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.
sp 500 cryptocurrency bitcoin crypto btc link cryptoUncategorized
Mortgage rates get close to the yearly high of 7.49%
Mortgage rates started the week at 7.28%, got as high as 7.47%, and ended at 7.39%. That’s close to the yearly high of 7.49%.

Mortgage rates shot up last week after a hawkish Federal Reserve meeting, even though they didn’t raise rates. In addition, jobless claims data had another solid print, showing that the labor market hasn’t broken yet, which led to more selling of the 10-year yield. Mortgage rates did find some relief on Friday as bond yields headed lower.
On housing inventory, new listings data saw a small decline last week, but active listings grew at a healthy clip. Purchase application data had another positive week, pulling off back-to-back positive prints.
Mortgage rates and the bond market
Last week was wild for the 10-year yield, as the key support line that I have been talking about for weeks broke after the Fed meeting, sending the 10-year yield to highs last seen in 2007. The 10-year yield fell on Friday, bringing some relief, but we got very close to yearly highs for mortgage rates. Mortgage rates started the week at 7.28%, got as high as 7.47%, and ended at 7.39%. The yearly high is 7.49%.
I have noticed for weeks now that the spreads between the 10-year yield and mortgage rates are better, so rates didn’t hit new highs last week, even with the 10-year yield breaking to new yearly highs.
The Fed sounded hawkish in their talk on Wednesday, but their rate hike cycle is over now, with the possibility of only one more rate hike if they think it’s warranted. The labor market isn’t as tight anymore, but jobless claims had another solid print and are near monthly lows. The four-week moving average for jobless claims is 217,000 — far from the key level of 323,000 level that I think would trigger a Fed pivot.
Weekly housing inventory data
Whenever mortgage rates rise, I fear that the weekly new listings data will decline more aggressively because homebuyers simply throw in the towel on listing their homes to sell because higher rates make it less attractive to sell and buy another home
Last week on CNBC, I talked about how I still believe that we will see some flat to positive year-over-year data because we have had to deal with higher rates for longer and we haven’t see new listings data take a meaningful fall lower. A lot of this has to do with this data line trending at the lowest levels ever. I explained my premise here in this interview on CNBC.
We have had some volatile weekly numbers in the new listings data recently, but even with the mortgage rate spike, the decline was orderly, as it has been all year. So, I am not worried about another leg lower in the data.
- Sept. 15: 61,852
- Sept. 23: 59,107
There is some positive news: weekly active listings grew 9,312. This is not at the levels that I think we should see with mortgage rates this high, which would be between 11,000-17,000 weekly, but it’s good enough, considering that we are almost done with September. I am a very pro-supply person because more supply brings balance. It’s been hard to grow the housing supply this year as home sales are stable compared to last year’s massive collapse in demand.
According to Altos Research:
- Weekly inventory change (Sept. 15–22): Inventory rose from 518,626 to 527,938
- Same week last year (Sept. 16-23): Inventory rose from 552,042 to 556,865
- The inventory bottom for 2022 was 240,194
- The inventory peak for 2023 so far is 527,938
- For context, active listings for this week in 2015 were 1,198,033
Historically, one-third of all homes have price cuts every year. Last week’s price cuts were lower than last year at the same time by 4%. This is happening with rates over 7%, too, and part of the reason is that housing inventory has been negative year over year since mid-June. Last year, inventory grew fast as the mortgage rate shock toward 7% created faster and higher price-cut data.
The housing market still has major affordability issues, and we are seeing a higher number of price cuts than in 2015-2017. Back then, we ran at 33%; in 2018 and 2019, it was 36%.
- 2021 28%
- 2022 41%
- 2023 37%
Purchase application data
Purchase application data was 2% higher last week, making the year-to-date count 17 positive prints, 18 negative prints, and one flat week. If we start from Nov. 9, 2022, it’s been 24 positive prints versus 18 negative prints and one flat week. The week-to-week data has gotten softer since mortgage rates have been trending above 7%. However, it’s not crashing like it was last year.
The week ahead: Housing and inflation data
We have another week of housing data ahead with new home sales, pending home sales, the S&P CoreLogic Case-Shiller home price index and the FHFA home price index. The pending home sales data should come in soft with the recent spike in mortgage rates. Also, we have the PCE inflation report, the main inflation data that the Federal Reserve tracks. As always, the Thursday jobless claims data is the key for this cycle and mortgage rates.
fed federal reserve home sales mortgage rates housing marketUncategorized
I Say We’re Setting Up For A Major Bottom
It’s almost impossible to call market tops and market bottoms using basic technical analysis tools like price and volume. Don’t get me wrong, that combination…

It's almost impossible to call market tops and market bottoms using basic technical analysis tools like price and volume. Don't get me wrong, that combination is my favorite during trend-following periods. But trying to spot bearish reversals is difficult when price action keeps riding higher and higher. The same is true in trying to spot bullish reversals when prices keep moving lower and lower. Maybe that seems unconventional to hard-core technicians, but I believe it's the reality. Too many folks say "when this line crosses that line, then this will happen". To me, that's following technical analysis and wearing blinders. Just my two cents.
I use technical price action to confirm what other signals are suggesting. We get plenty of signals on a regular basis - some short-term in nature, others long-term - if we're only willing to listen. While I've been bullish since June 2022, I do recognize short-term warning signals that tell us that risks of remaining long have increased substantially. In mid-July, I turned very cautious short-term and discussed those signals in a "Your Daily 5" episode that aired on July 19th. Let me pull up an S&P 500 chart, so you can see where U.S. equities stood when I fired this warning shot:
There were several reasons for the stock market bulls to hit quicksand. Tesla (TSLA), a Wall Street darling and a favorite stock of mine, suggested a possible 20% drop. That call aired the day of TSLA's top and TSLA fell closer to 30% in less than one month. These signals work and help us to manage risk! As I always say, they do NOT guarantee future price action, but they make us aware of increasing risk and that's how you invest more successfully. Since that July top, I've encouraged our EB members to tread very cautiously, whatever that means to each individual member. To some, it's being in cash. To others, it might simply mean to avoid leverage on the long side. But this cautious period is coming to an end.
If you want to see what was discussed on July 19th and why I felt the stock market was in short-term trouble, check out the Your Daily 5 recording on YouTube!
I absolutely LOVE when my signals take the opposite view of the masses. And now that everyone believes we're resuming the prior bear market, my signals are saying HOGWASH. Could we continue to proceed lower? Sure. There are never any guarantees with the stock market. But I see signs that suggest shorting is a VERY HIGH RISK strategy, with those risks growing every day. I'm discussing one major reason why in our FREE EB Digest newsletter that will be published early Monday morning, before the stock market opens. If you're not already an EB Digest subscriber, it's 100% free with no credit card required. Simply CLICK HERE and enter your name and email address. I'll discuss Reason #1 to turn bullish tomorrow morning. And I'll also focus on other reasons to be thinking bullish thoughts when I publish the EB Digest on Wednesday and Friday. Don't wait until it's too late. Check them out NOW!
Happy trading!
Tom
sp 500 equities-
International16 hours ago
Defunct ‘Disinformation Governance Board’ Sought To Censor Opposing Views On Racial Justice, Afghan Withdrawal, & Other Political Subjects
-
Uncategorized16 hours ago
Coinbase secures AML registration from the Bank of Spain
-
International18 hours ago
Air Force General Defends Memo That Predicted War With China By 2025
-
Government20 hours ago
Republicans Embrace Ballot Harvesting for 2024, Some Foresee Legal Battles
-
Uncategorized12 hours ago
FTX’s former external legal team disputes involvement in fraud allegations
-
International23 hours ago
Ukraine Says Sevastopol HQ Strike Left Dozens Of Casualties “Including Senior Leadership”
-
Government21 hours ago
Gov. Newsom Attacks Federal Judge As Child-Killing, Extremist, Right-Wing Zealot Owned By The NRA
-
Uncategorized21 hours ago
Binance.US scores against SEC, Mt. Gox delay repayments, and other news: Hodler’s Digest, Sept. 17-23